Abstract
Rationale
The purpose of this study is to analyse the effectiveness of flupentixol compared to other first- and second-generation antipsychotics for the treatment of schizophrenia in routine care.
Method
A retrospective cohort study was conducted using administrative data from four sickness funds covering 12.6 million insured. Patients discharged from hospital in 2003 with an ICD-10 diagnosis of schizophrenia were followed for 12 months. Rehospitalisation during follow-up was analysed using a hurdle regression model. Treatment costs were defined as cost of pharmaceutical and cost of inpatient care. Two thousand eight hundred ninety insured were included, of which 177 were treated with flupentixol during follow-up, while 429 and 2,284 were treated with other first-and second-generation antipsychotics, respectively.
Results
Compared to patients treated with flupentixol (21.0 days), predicted hospitalisation did not differ significantly for patients treated with other first- (21.3 days, p = 0.8313) or second-generation antipsychotics (25.6 days, p = 0.4035). Predicted treatment costs for the average patient were 4,193 € if treated with flupentixol, 4,846 € if treated with other first-generation antipsychotic, and 6,523 € if treated with a second-generation antipsychotic. Second-generation antipsychotics showed a clear advantage over flupentixol concerning extrapyramidal symptoms co-medication.
Conclusion
The effectiveness of flupentixol preventing relapse in patients with schizophrenia appears to be similar to that of other first- and second-generation antipsychotics. However, the low treatment costs for patients treated with flupentixol could be explained by the small number of patients with readmissions (70 insured) and the larger share of patients treated with its depot formulation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Almond S, Knapp M, Francois C et al (2004) Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 184:346–351
Budde G (1992) Efficacy and tolerability of flupenthixol decanoate in the treatment of depression and psychosomatic disorders: a multicenter trial in general practice. Prog Neuropsychopharmacol Biol Psychiatr 16:677–689
Conley RR, Love RC, Kelly DL et al (1999) Rehospitalisation rates of patients recently discharged on a regimen of risperidone or clozapine. Am J Psychiatry 156:863–868
Conley RR, Kelly DL, Love RC et al (2003) Rehospitalization risk with second-generation and depot antipsychotics. Ann Clin Psychiatry 15:23–31
Crossley NA, Constante M, McGuire P, Power P (2010) Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. Br J Psychiatry 196:434–439
Csernansky JG, Mahmoud R, Brenner R (2002) A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346:16–22
Davis J, Chen N, Glick I (2003) A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60:553–564
Eberhard G, Hellbom E (1986) Haloperidol decanoate and flupentixol decanoate in schizophrenia. A long-term double-blind cross-over comparison. Acta Psychiatr Scand 74:255–262
Gattaz WF, Diehl A, Geuppert MS et al (2004) Olanzapine versus flupentixol in the treatment of inpatients with schizophrenia: a randomized double-blind trial. Pharmacopsychiatry 37:279–285
Geddes J, Freemantle N, Harrison P et al (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321:1371–1376
Gruber AJ, Cole JO (1991) Antidepressant effects of flupenthixol. Pharmacotherapy 11:450–459
Haro JM, Edgell ET, Frewer P et al (2003) The European schizophrenia outpatient health outcomes (SOHO) study: baseline findings across country and treatment. Acta Psychiatr Scand 107:7–15
Hertling I, Philipp M, Dvorak A et al (2003) Flupentixol versus risperidone: subjective quality of life as an important factor for compliance in chronic schizophrenic patients. Neuropsychobiology 47:37–46
Jones PB, Barnes TR, Davies L et al (2006) Randomized controlled trial of the effect on quality of life of second- vs. first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry 63:1079–1087
Kilian R, Angermeyer MC, Becker T (2004) Methodische Grundlagen naturalistischer Beobachtungsstudien zur ökonomischen evaluation der Neuroleptikabehandlung bei schizophrenen Erkrankungen. Gesundheitswesen 66:180–185
Kissling W, Höffler J, Seemann U et al (1999) Direct and indirect costs of schizophrenia. Fortschr Neurol Psychiatr 67:29–36
Knudsen P (1985) Chemotherapy with neuroleptics. Clinical and pharmacokinetic aspects with a particular view to depot preparations. Acta Psychiatr Scand 322:51–75
Konnopka A, Klingberg S, Wittorf A, König HH (2009) The cost of schizophrenia in Germany: a systematic review of the literature. Psychiat Prax 36:211–218
Kühn KU, Meyer K, Maier W (2000) Flupentixol-a partial atypical neuroleptic. Fortschr Neurol Psychiatr 68:38–41
Lieberman JA, Stroup TS, McEvoy JP et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223
Lyons JS, O'Mahoney MT, Miller SI et al (1997) Predicting readmission to the psychiatric hospital in a managed care environment: implications for quality indicators. Am J Psychiatry 154:337–340
Möller HJ (1999) Atypical neuroleptics: a new approach in the treatment of negative symptoms. Eur Arch Psychiatr Clin Neurol sci 24:99–107
Müller P, Nerenz H, Schaefer E (2002) The risk of rehospitalisation during therapy with atypical and typical neuroleptics—a contribution to differential indication. Psychiatr Prax 29:388–391
Pach J, Bertling R, Finkbeiner T et al (1998a) Rezidive bei schizophrenen Erkrankungen unter Depot-Neuroleptika. Ergebnisse einer 1-jährigen Doppelblindstudie mit Flupentixol-Decanoat. Psychopharmakotherapie 5:161–165
Pach J, Finkbeiner T, Glaser T et al (1998b) Positiv- und Negativsymptomatik bei chronisch schizophrenen Patienten unter Erhaltungstherapie mit Flupentixoldecanoat im 12-Monatsverlauf. Fortschr Neurol Psychiatr 66:442–449
Philipp M, Lesch OM, Schmauss M et al (2003) Comparative effectiveness of flupentixol and risperidone on negative symptoms of schizophrenia. Psychiatr Prax 30:94–96
Rosenheck R, Perlick D, Bingham S et al (2003) Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 290:2693–2702
Saha S, Chant D, Welham J, McGrath J (2005) A systematic review of the prevalence of schizophrenia. PLoS Med 2:e141
Sernyak MJ, Leslie D, Rosenheck R (2003) Use of system-wide outcomes monitoring data to compare the effectiveness of atypical neuroleptic medications. Am J Psychiatry 160:310–315
Stargardt T, Weinbrenner S, Busse R et al (2008) Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care. J Ment Health Policy Econ 11:89–97
Thieda P, Beard S, Richter A et al (2003) An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv 54:508–516
Tiihonen J, Wahlbeck K, Lönnqvist J et al (2006) Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 333:224
Tollefson GD, Beasley CM, Tran PV et al (1997) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154:457–465
Wahlbeck K, Cheine M, Essali A et al (1999) Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 156:990–999
Weiden PJ, Olfson M (1995) Cost of relapse in schizophrenia. Schizophr Bull 21:419–429
Weinbrenner S, Assion HJ, Stargardt T et al (2008) Drug prescription patterns in schizophrenia outpatients: analysis of data from German health insurance fund. Pharmacopsychiatry 41:1–6
Zhang PL, Santos JM, Newcomer J et al (2004) Impact of atypical antipsychotics on quality of life, selfreport of symptom severity, and demand of services in chronically psychotic patients. Schizophr Res 71:137–144
Acknowledgements
This study was kindly supported by an investigator-initiated trial grant from Bayer Vital GmbH. We are very grateful to the Techniker Krankenkasse, AOK Berlin, AOK Baden-Wuerttemberg and AOK Westfalen-Lippe for their kind support in granting access to the sickness fund databases and for their help with data extraction.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stargardt, T., Mavrogiorgou, P., Gericke, C.A. et al. Effectiveness and costs of flupentixol compared to other first- and second-generation antipsychotics in the treatment of schizophrenia. Psychopharmacology 216, 579–587 (2011). https://doi.org/10.1007/s00213-011-2256-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-011-2256-x